Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | UBE2M | P61081 | 1/20 | 0.30 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1061205 | 0.90 | HPGD (0.35) | HPGDMAPK1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL14780908 | 0.89 | HPGD (0.34) | HPGD | |
| SCHEMBL1062229 | 0.81 | HPGD (0.35) | HPGDALDH1A1KDM4E | |
| SCHEMBL12963047 | 0.81 | HPGD (0.35) | HPGDMAPK1L3MBTL1THRB | |
| SCHEMBL1060720 | 0.74 | HPGD (0.34) | HPGDMAPK1L3MBTL1KDM4ETHRB | |
| SCHEMBL14780905 | 0.73 | HPGD (0.33) | HPGDMAPK1L3MBTL1THRBHDAC4 | |
| SCHEMBL1062597 | 0.72 | MEN1 (0.41) | HPGDL3MBTL1ALDH1A1THRB | |
| SCHEMBL1063037 | 0.71 | HPGD (0.35) | HPGDMAPK1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL10314556 | 0.69 | ELANE (0.35) | MAPK1KDM4E | |
| SCHEMBL3401033 | 0.68 | TARBP2 (0.49) | ALDH1A1KDM4EHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | HPGD 920/4885MAPK1 2399/4885L3MBTL1 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.